Undecimal Bio launches with $18M to take siRNA beyond the liver, in a seed round co-led by 4BIO Capital

Undecimal’s seed funding will be used for its work on delivery molecules, such as conjugates, as well as therapeutic siRNA, CEO and co-founder Yaniv Erlich told Endpoints News in an interview. So far, the company has tested its platform, which it calls DELiveri, in a number of different cell lines and will continue to test it in primary human cells, he said.

Read more on Endpoints News.